Skip to NavigationSkip to content

Lamberto Andreotti new head of Bristol-Myers Squibb

Published on: 04/03/10

Bristol-Myers Squibb has appointed Lamberto Andreotti its new chief executive with effect from 4 May, succeeding James Cornelius who will remain as the company’s chairman.

Andreotti said: “Jim successfully led our transformation into a next-generation biopharma leader with his strategic leadership and consistent focus on delivering our commitments. I am personally grateful for this opportunity to lead Bristol-Myers Squibb in the next phase of our biopharma journey.

Andreotti is currently responsible for the BMS’ global pharmaceutical business, holding the roles of president and chief operating officer.

He has been with the company for 12 years in senior leadership roles, both internationally and in the US. Prior to joining BMS he held senior roles at KABI Pharmacia and then at Pharmacia & Upjohn.

“While challenges lie ahead, we are confident we can overcome them as we continue to successfully execute and deliver operationally, financially and strategically to maximise our future opportunities. As we succeed, the ultimate beneficiaries are patients who we help prevail against serious diseases,” he added.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches